Review the ECLIPSE study published in New England Journal of Medicine.  See the data

Early detection saves lives1

Screening matters for your employees


of people diagnosed with CRC in early stages survive2


of people diagnosed with CRC in late stages survive2

Screening is key to reducing colorectal cancer (CRC) mortality

CRC is the 2nd leading cause of cancer deaths among men and women in the US—yet more than half of eligible workers (age 45-64 years) are not up to date with CRC screening.2,3

~60% of all CRC deaths could be prevented with regular screening.4,5

You can remove barriers to screening

Current CRC screening options exist, but they can be time-consuming and uncomfortable, which may be why your employees remain unscreened.1,6-10 Increase CRC screening compliance with an accurate blood-based approach.11

of eligible patients preferred blood-based screening12

Shield™, an easy-to-complete blood test11,13

  • Requires no preparation13
  • No extra time away from work13
  • Detects CRC with high accuracy11
See the data

Make a difference and take control

You can now offer eligible employees blood-based screening for CRC, helping to increase screening compliance.

With Shield, a convenient and proven blood test, you can help employees detect CRC early—when it's most treatable.1,10-12

Offer Shield as a benefit

Protect your employees and your business

Protect your employees and your business

Late-stage CRC treatment is more expensive than early-stage treatment.14

Stage 4 CRC treatment costs 3x as much as CRC Stage 1. CRC screening and early cancer detection helps with productivity and cost management. Screening saves lives, and education is the best way to encourage your employees to get screened.14

Let's get screened

Guardant Health partners with leading employers like you to help drive CRC screening compliance. Shield can be easily integrated or adopted to your current education and awareness programs, worksite health center, and on-site screening programs.

Learn how Shield fits into your organization

Please fill out the information below or email us directly and we will be in touch!

    Shield™ is a qualitative laboratory developed test intended to detect colorectal cancer by identifying genomic and epigenomic alterations in cell-free DNA in plasma from blood collected in Guardant blood collection tubes.
    • The assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods
    • Patients with an “abnormal signal detected” Shield result should be referred for colonoscopic evaluation
    • A “normal signal detected” Shield result does not preclude the presence of colorectal cancer, and patients should continue participating in guideline-recommended screening programs
    • Shield was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the US FDA
    References 1. Kim ST, Raymond VM, Park JO, et al. Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (ctDNA) improves assay sensitivity in early-stage colorectal cancer (CRC). Cancer Res. 2019;79(suppl 13):916. doi:10.1158/1538-7445.AM2019-916 2. National Cancer Institute. Colon and rectum stage distribution of SEER incidence cases, 2009-2018. Accessed March 18, 2024. 3. Doubeni CA, Fedewa SA, Levin TR, et al. Modifiable failures in the colorectal cancer screening process and their association with risk of death. Gastroenterology. 2019;156(1):63-74. doi:10.1053/j.gastro.2018.09.040 4. Fight Colorectal Cancer: Stats and Facts. Accessed August 2020. 5. CDC Press Release. Colorectal cancer screening rates remain low. Accessed October 2021. 6. American Society of Clinical Oncology. Colorectal cancer: statistics. website. Updated May 2022. Accessed October 24, 2022. 7. Liles EG, Coronado GD, Perrin N, et al. Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: a randomized trial. Cancer Treat Res Commun. 2017;10:27-31. doi:10.1016/j.ctarc.2016.12.004 8. Denberg TD, Melhado TV, Coombes JM, et al. Predictors of nonadherence to screening colonoscopy. J Gen Intern Med. 2005;20(11):989-995. doi:10.1111/j.1525-1497.2005.00164.x 9. Parks P. Innovation in colorectal cancer screening - there has to be a better way. Am J Manag Care. Published October 9, 2017. Accessed September 17, 2021. 10. Westesson O, Axelrod H, Dean J, et al. Integrated genomic and epigenomic cell-free DNA (cfDNA) analysis for the detection of early-stage colorectal cancer. Cancer Res. 2020;80(suppl 16):2316. doi:10.1158/1538-7445.AM2020-2316 11. Chung DC, Gray DM II, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med. 2024;390(11):973-983. doi:10.1056/NEJMoa2304714 12. Adler A, Geiger S, Keil A, et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014;14:183. doi:10.1186/1471-230X-14-183 13. Rich T, Raymond V, Lang K. Where are we today? Efforts to understand strategies and barriers to physician issuance of a recommendation for colorectal cancer screening: a systematic review. Gastroenterology. 2020;158(6 suppl 1):S-918. doi:10.1016/S0016-5085(20)32981-4 14. No time for guesswork: when it comes to cancer, evidence-based interventions save lives and dollars. ScreenOutCancer. Accessed November 14, 2022.